TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

NCT03829436 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma
Metastatic Castration Resistant Prostate Cancer
Renal Cell Carcinoma
Non-small Cell Lung Cancer
Colorectal Cancer
Squamous Cell Carcinoma of Head and Neck
Triple-Negative Breast Cancer
Urothelial Carcinoma
Cholangiocarcinoma
GastroEsophageal Cancer
Pancreatic Cancer
Sarcoma

Interventions

DRUG: Part 1 TPST-1120
DRUG: Part 2 TPST-1120 + nivolumab
DRUG: Part 3 TPST-1120
DRUG: Part 4 TPST-1120 + nivolumab

Sponsor

Tempest Therapeutics